IDYA - IDEAYA Biosciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
IDYA price evolution
IDYA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $183.96 | $109.1 | $157.78 | |
| Short term investments | $518.61 | $590.43 | $368.1 | |
| Net receivables | $0.02 | $0 | $0.01 | $0.02 |
| Inventory | ||||
| Total current assets | $932.21 | $713.18 | $709.35 | $532.63 |
| Long term investments | $251.07 | $242.64 | $107.49 | |
| Property, plant & equipment | $26.62 | $8.43 | $8.69 | $8.41 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $260.48 | $252.17 | $116.68 | |
| Total investments | $769.68 | $833.06 | $475.59 | |
| Total assets | $1239.87 | $973.66 | $961.53 | $649.32 |
| Current liabilities | ||||
| Accounts payable | $12.57 | $15.89 | $6.29 | $6.6 |
| Deferred revenue | ||||
| Short long term debt | $0.61 | $1.15 | $1.75 | |
| Total current liabilities | $40.66 | $40.74 | $24.96 | $27.1 |
| Long term debt | $1.26 | $1.26 | $1.13 | |
| Total noncurrent liabilities | $1.26 | $1.26 | $1.13 | |
| Total debt | $1.87 | $2.41 | $2.87 | |
| Total liabilities | $59.45 | $42.01 | $26.22 | $28.23 |
| Shareholders' equity | ||||
| Retained earnings | -$492.53 | -$440.71 | -$387.94 | -$348.36 |
| Other shareholder equity | $3.84 | -$1.42 | -$0.92 | $0.56 |
| Total shareholder equity | $931.66 | $935.31 | $621.09 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $157.78 | $68.74 | $92.15 | $72.14 |
| Short term investments | $368.1 | $296.2 | $154.72 | $211.55 |
| Net receivables | $0.02 | $0.21 | $1.1 | $1.88 |
| Inventory | ||||
| Total current assets | $532.63 | $370.45 | $251 | $288.61 |
| Long term investments | $107.49 | $8.32 | $121.29 | |
| Property, plant & equipment | $8.41 | $8.99 | $8.66 | $9.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $116.68 | $17.52 | $130.35 | $9.66 |
| Total investments | $475.59 | $304.51 | $276.02 | $211.55 |
| Total assets | $649.32 | $387.97 | $381.35 | $298.27 |
| Current liabilities | ||||
| Accounts payable | $6.6 | $4.28 | $2.1 | $0.95 |
| Deferred revenue | ||||
| Short long term debt | $1.75 | $1.87 | $1.7 | $1.54 |
| Total current liabilities | $27.1 | $31.72 | $45.16 | $38.64 |
| Long term debt | $1.13 | $1.61 | $3.48 | $5.18 |
| Total noncurrent liabilities | $1.13 | $6.8 | $34.67 | $61.35 |
| Total debt | $2.87 | $3.48 | $5.18 | $6.72 |
| Total liabilities | $28.23 | $38.51 | $79.83 | $100 |
| Shareholders' equity | ||||
| Retained earnings | -$348.36 | -$235.4 | -$176.75 | -$126.99 |
| Other shareholder equity | $0.56 | -$2.87 | -$0.71 | $0.01 |
| Total shareholder equity | $621.09 | $349.45 | $301.51 | $198.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.92 | |||
| Cost of revenue | ||||
| Gross Profit | $3.92 | |||
| Operating activities | ||||
| Research & development | $54.53 | $42.8 | $38.77 | |
| Selling, general & administrative | $10.39 | $8.21 | $7.07 | |
| Total operating expenses | $66.89 | $64.93 | $51.02 | $45.84 |
| Operating income | -$64.93 | -$51.02 | -$41.92 | |
| Income from continuing operations | ||||
| EBIT | -$52.77 | -$39.57 | -$33.95 | |
| Income tax expense | ||||
| Interest expense | $15.07 | |||
| Net income | ||||
| Net income | -$51.82 | -$52.77 | -$39.57 | -$33.95 |
| Income (for common shares) | -$52.77 | -$39.57 | -$33.95 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $23.39 | $50.93 | $27.94 | $19.54 |
| Cost of revenue | ||||
| Gross Profit | $23.39 | $50.93 | $27.94 | $19.54 |
| Operating activities | ||||
| Research & development | $129.51 | $89.54 | $58.16 | $39.7 |
| Selling, general & administrative | $28.31 | $23.9 | $20.05 | $15.18 |
| Total operating expenses | $157.81 | $113.43 | $78.21 | $54.88 |
| Operating income | -$134.43 | -$62.5 | -$50.27 | -$35.34 |
| Income from continuing operations | ||||
| EBIT | -$112.96 | -$58.66 | -$49.76 | -$34.49 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$112.96 | -$58.66 | -$49.76 | -$34.49 |
| Income (for common shares) | -$112.96 | -$58.66 | -$49.76 | -$34.49 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$52.77 | -$39.57 | -$33.95 | |
| Operating activities | ||||
| Depreciation | $1.1 | $1.08 | $1.02 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.73 | $6.31 | $4.8 | |
| Total cash flows from operations | -$32.88 | -$43.81 | -$23.75 | |
| Investing activities | ||||
| Capital expenditures | -$0.97 | -$1.32 | -$0.84 | |
| Investments | $69.53 | -$352.65 | -$111.11 | |
| Total cash flows from investing | -$305.45 | $68.56 | -$353.97 | -$111.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $39.18 | $349.11 | $98.71 | |
| Net borrowings | ||||
| Total cash flows from financing | $674.8 | $39.18 | $349.11 | $140.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $243.42 | $74.86 | -$48.67 | $5.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$112.96 | -$58.66 | -$49.76 | -$34.49 |
| Operating activities | ||||
| Depreciation | $4.01 | $2.1 | $1.73 | $1.38 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $18.49 | $11.63 | $8.24 | $3.61 |
| Total cash flows from operations | -$115.22 | -$87.17 | -$55.78 | $55.46 |
| Investing activities | ||||
| Capital expenditures | -$2.37 | -$3.44 | -$2.64 | -$0.49 |
| Investments | -$156.09 | -$29.96 | -$67.02 | -$145.75 |
| Total cash flows from investing | -$158.46 | -$33.4 | -$69.67 | -$146.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $320.54 | $97.17 | $145.45 | $128.75 |
| Net borrowings | ||||
| Total cash flows from financing | $362.72 | $97.17 | $145.45 | $128.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $89.04 | -$23.41 | $20.01 | $37.97 |
News
Fundamentals
| Market cap | $1.81B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 86.36M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$178.12M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -10.18 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.06 |
|---|---|
| ROA | -18.63% |
| ROE | N/A |
| Debt/Equity | 0.05 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 22.93 |
| Quick ratio | N/A |